The Gastrointestinal Therapeutics market is booming, projected to reach $55.9 billion by 2033, driven by increasing prevalence of IBD, IBS, and GERD. This comprehensive analysis explores market trends, key players (Abbott, AbbVie, Pfizer), and future growth opportunities in biologics, targeted therapies, and emerging markets.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.